BusinessRhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a calcium release-activated calcium (CRAC) channel inhibitor and RP10107, a glutaminase inhibitor at the 2018 AACR Annual MeetingBy Nasdaq OMXApr 10, 2018, 11:00 AM UTC
BusinessRhizen Pharmaceuticals S.A. announces clinical and preclinical data presentations at the upcoming 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, GA, USABy Nasdaq OMXDec 5, 2017, 12:00 PM UTC
